Association of British Clinical Diabetologists

ABCD worldwide audits

Home Live ABCD audits of new therapies and devices All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits

Above - Global projections of the number of people with diabetes 2013 and 2035. From the IDF Diabetes Atlas, 6th edition, 2013 - click to enlarge


Above: Proportion of deaths due to diabetes in people under 60 years of age, 2013. From the IDF Diabetes Atlas, 6th edition, 2013 - click to enlarge


Above: a picture of an endobarrier in position - click for more information

ABCD worldwide audits

Worldwide audit of new diabetes therapies

ABCD is now cloning some of its N3 audit tools onto a secure server accessible world-wide for audit purposes. Everything is exactly the same except that the patient identifier is encrypted. Instead of users registering centres and sites as in the N3 versions, users register countries and centres in those countries. The sophisticated analysis tool will be available for Centres to analyse their data, but super-users within the country will be able to analyse the national data using the same facilities. At the same time all the anonymised data will be available for worldwide data analysis.

The tools to be made available in this way were with regard to exenatide qw, dapagliflozin, canagliflozin and FreeStyle Libre and always the first country to register is Northern Ireland. The Northern Ireland centres are historically very active contributors to ABCD nationwide audits, but Northern Ireland is not on N3 and hence has to use the worldwide tool.

Anyone from any Centre in any Country interested in registering to use the audit tools in this way should fill in the online application form or in the case of FreeStyle Libre this application form For further information contact Dr Bob Ryder, clinical lead, ABCD nationwide audits of new diabetes therapies and devices by clicking here.


Endobarrier worldwide registry
ABCD has established a worldwide Endobarrier registry of to capture routine clinical data on safety and efficacy of this exciting new treatment. Because the technology is based on the technologies developed for our other audits of new therapies, the tool has the well honed bespoke facility for capturing changes in other diabetes therapies with time. Also the sophisticated data analysis tool developed for the exenatide QW, dapagliflozin, canagliflozin and FreeStyle Libre audit tools. The analysis is available to deploy for use by individual centres, individual countries, groups of countries, or all worldwide data.
Click here for more information.



   Main ABCD homepage

ABCD Closed-Loop audit

ABCD NHS England nationwide closed loop pilot audit

ABCD Dexcom audit

ABCD Omnipod Worldwide audit

ABCD FreeStyle Libre audit

ABCD Testosterone & Diabetes Worldwide audit 

ABCD oral semaglutide audit

ABCD semaglutide audit

ABCD COVID-19 & Diabetes audit


ABCD canagliflozin audit

ABCD dapagliflozin audit

ABCD empagliflozin audit

 ABCD exenatide QW audit

ABCD IDegLira audit

ABCD degludec audit

ABCD liraglutide audit

ABCD exenatide audit

ABCD worldwide audits

EndoBarrier worldwide registry

Contact us


Working to support high quality diabetes care in the UK